EPIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EPIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
ESSA Pharma's adjusted revenue per share for the three months ended in Dec. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-05-02), ESSA Pharma's current stock price is $6.825. ESSA Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.00. ESSA Pharma's Cyclically Adjusted PS Ratio of today is .
The historical data trend for ESSA Pharma's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESSA Pharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, ESSA Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ESSA Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where ESSA Pharma's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, ESSA Pharma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0 | / | 125.4675 | * | 125.4675 | |
= | 0.000 |
Current CPI (Dec. 2023) = 125.4675.
ESSA Pharma Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201403 | 0.000 | 98.604 | 0.000 |
201406 | 0.000 | 99.473 | 0.000 |
201409 | 0.000 | 99.394 | 0.000 |
201412 | 0.000 | 98.367 | 0.000 |
201503 | 0.000 | 99.789 | 0.000 |
201506 | 0.000 | 100.500 | 0.000 |
201509 | 0.000 | 100.421 | 0.000 |
201512 | 0.000 | 99.947 | 0.000 |
201603 | 0.000 | 101.054 | 0.000 |
201606 | 0.000 | 102.002 | 0.000 |
201609 | 0.000 | 101.765 | 0.000 |
201612 | 0.000 | 101.449 | 0.000 |
201703 | 0.000 | 102.634 | 0.000 |
201706 | 0.000 | 103.029 | 0.000 |
201709 | 0.000 | 103.345 | 0.000 |
201712 | 0.000 | 103.345 | 0.000 |
201803 | 0.000 | 105.004 | 0.000 |
201806 | 0.000 | 105.557 | 0.000 |
201809 | 0.000 | 105.636 | 0.000 |
201812 | 0.000 | 105.399 | 0.000 |
201903 | 0.000 | 106.979 | 0.000 |
201906 | 0.000 | 107.690 | 0.000 |
201909 | 0.000 | 107.611 | 0.000 |
201912 | 0.000 | 107.769 | 0.000 |
202003 | 0.000 | 107.927 | 0.000 |
202006 | 0.000 | 108.401 | 0.000 |
202009 | 0.000 | 108.164 | 0.000 |
202012 | 0.000 | 108.559 | 0.000 |
202103 | 0.000 | 110.298 | 0.000 |
202106 | 0.000 | 111.720 | 0.000 |
202109 | 0.000 | 112.905 | 0.000 |
202112 | 0.000 | 113.774 | 0.000 |
202203 | 0.000 | 117.646 | 0.000 |
202206 | 0.000 | 120.806 | 0.000 |
202209 | 0.000 | 120.648 | 0.000 |
202212 | 0.000 | 120.964 | 0.000 |
202303 | 0.000 | 122.702 | 0.000 |
202306 | 0.000 | 124.203 | 0.000 |
202309 | 0.000 | 125.230 | 0.000 |
202312 | 0.000 | 125.468 | 0.000 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of ESSA Pharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Virsik | officer: Chief Operating Officer | 131 ESCANYO WAY, PORTOLA VALLEY CA 94028 |
David Ross Parkinson | director, officer: Chief Executive Officer | C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Franklin M Berger | director | 1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
Lauren Merendino | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David S. Wood | officer: Chief Financial Officer | 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4 |
Biotech Growth N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Philip W. Kantoff | director | 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf I Gp Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Partners Os Ltd. | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Inc/il | 10 percent owner | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Partners L P/il | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire PRNewswire • 06-06-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire • 11-21-2023
By PRNewswire PRNewswire • 07-12-2022
By PRNewswire PRNewswire • 02-07-2023
By PRNewswire PRNewswire • 11-10-2022
By GuruFocus Research • 11-23-2023
By PRNewswire PRNewswire • 10-26-2022